- Home
- TYG vs URGN Comparison
TYG vs URGN Comparison
Compare TYG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYG | URGN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TYG | URGN |
|---|---|---|
| Price | $50.18 | $18.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 100.8K | ★ 697.0K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 11.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $119.37 |
| Revenue Next Year | N/A | $64.79 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.73 | $3.42 |
| 52 Week High | $50.93 | $30.00 |
Technical Indicators
Market Signals| Indicator | TYG | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | 37.32 |
| Support Level | $42.25 | $16.47 |
| Resistance Level | N/A | $20.44 |
| Average True Range (ATR) | 0.88 | 1.59 |
| MACD | 0.12 | -0.18 |
| Stochastic Oscillator | 74.18 | 13.39 |
Price Performance
Historical ComparisonAbout TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.